🔗 Share this article

While the US proceeds with historic revisions to its immunization recommendations, one figure appears unexpectedly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning coronavirus vaccines in the pandemic and has zeroed in on potential deaths after Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Health officials had intended to unveil sweeping changes to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of alignment with many the world with no evidence for benefit. The planned update has been postponed until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to present at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

The acting appointment might represent a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood shot schedules in the US in order to be more like Denmark, a nation with nationalized medicine and a population about the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Background

Dr. Høeg has no apparent experience in medication creation, regulation or management, which has been customary for previous leaders of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “grasp laws and regulations and the research of drug development”, said Janet Woodcock. “Frankly, she doesn’t have the sort of resume that previous people who headed the center have had.”

CDER has an immense portfolio at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the generic drug division authorizes thousands of generic medications. There is also a biologic copycat branch, OTC medication office and so forth, and all of those must be supervised,” Dr. Woodcock explained. “The thing you neglect, that is the part that I always told people is going to cause problems.”

There is also, a substantial leadership aspect to the role, which supervises in excess of 5,000 personnel. “It is a huge management job, if you do it right,” Woodcock added.

Response and Disputed Initiatives

In response to questions about Høeg’s credentials and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a representative stated that the “questions stem from inaccurate presumptions”.

“Her experience is consistent with the duties of her job,” the spokesperson stated, citing the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed rapid drug-approval program that reportedly worried her former heads. “By what process are these medications being picked for this voucher program? Who is making the calls?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he said, “the agency looks to be trending towards more relaxed oversight of most medications, except for vaccines.”

Public Track Record on Vaccines

With immunizations, Høeg has a clearer, if concerning, history, Howard observe. She released a study using unconfirmed crowd-sourced reports to determine the frequency of myocarditis following COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new administration included changing rules for recently developed shots and halting “unnecessary” immunizations, she said after the election on a online show. At the FDA, Høeg has reportedly proposed barring teenage boys from receiving Covid vaccinations.

“She’s an complete ideologue who starts off with her preconceived notions and tailors the evidence to retrofit the data in a very disingenuous, dishonest manner,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|